Annovis Bio, Inc. (ANVS) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.00

From 52W high−80.78%

Volume633049.00

Market cap$41.83M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.00

From 52W high

−80.78%

Volume

633049.00

Market cap

$41.83M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

P/E (TTM)

—

RSI (14)

31.5

MomentumView details →

1D Return

−1.35%

YTD Return

−71.53%

SummaryUpdated Jun 1, 2026

Annovis Bio, Inc. (NASDAQ:ANVS) is a clinical-stage biotechnology company founded in 2008 and headquartered in Berwyn, Pennsylvania. The company went public in January 2020 and focuses on developing novel drug treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Annovis operates as a drug platform company, meaning it develops a portfolio of compounds that can potentially treat multiple neurological conditions through similar mechanisms of action.

Ask drillr about Annovis Bio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−9.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

1164.01%

ROA (TTM)

−224.73%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+12.25%

FCF YoY

−75.52%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+30.69%

EBITDA YoY

—

MomentumView details →

1D Return

−1.35%

YTD Return

−71.53%

1Y Return

−52.42%

RSI (14)

31.5

vs 50D SMA

−29.88%

vs 200D SMA

−51.57%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

2.95x

Quick Ratio

2.95x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.40

EPS Surprise

11.76%

Beats (12Q)

5/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

−19.24%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−49.52M

Op. CF (TTM)

−43.34M

Next earningsNov 11, 2026 →

Latest newsMore news →

ANNOVIS BIO announced that its Phase 3 clinical trial for Alzheimer's disease has completed enrollment of all subjects, with key data and regulatory submission expected in 2027.55d ago

Similar companies

Elicio Therapeutics, Inc.ELTX Adicet Bio, Inc.ACET Dogwood Therapeutics, Inc.DWTX INmune Bio, Inc.INMB Aldeyra Therapeutics, Inc.ALDX XOMA CorporationXOMAO Find similar companies →

Latest newsMore news →

Annovis Bio announced a collaboration with Weave Bio, an AI regulatory content and knowledge management platform, to support its planned New Drug Application for buntanetap in Alzheimer's disease.26d ago ANNOVIS BIO announced that its Phase 3 clinical trial for Alzheimer's disease has completed enrollment of all subjects, with key data and regulatory submission expected in 2027.55d ago Annovis Bio, Inc. reported its financial results for the second quarter ended June 30, 2026.66d ago